CYTH - Cyclo Therapeutics soars 10% on launch of Phase 3 Trappsol Cyclo study in rare genetic disorder

Cyclo Therapeutics (CYTH) jumps 10% premarket after commencing Phase 3 study (TransportNPC) evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for the treatment of Niemann-Pick Disease Type C1 (NPC1), a rare genetic disease. The study intends to enroll at least 93 pediatric and adult patients with NPC1. The study duration is 96 weeks and includes an interim analysis at 48 weeks.Topline results from the interim analysis are expected in H1 2023. The primary objective is to evaluate the mean change from baseline to 48 weeks or 96 weeks as measured by improvement in Trappsol Cyclo vs. placebo- based on regulatory preferences.The TransportNPC study has the regulatory and IRB approval required to commence patient enrollment, and site activation is underway.

For further details see:

Cyclo Therapeutics soars 10% on launch of Phase 3 Trappsol Cyclo study in rare genetic disorder